arrow
J

Joaquina Baranda

University of Kansas Medical Center
H指数:27
被引数:3,924

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Enfortumab vedotin in patients with advanced non-small cell lung cancer after disease progression on platinum- and PD-1/PD-L1 inhibitor-containing regimens: Phase 2 international multicenter EV-202 study

恩沃利单抗(enfortumab vedotin)在铂类和PD-1/PD-L1抑制剂方案治疗后疾病进展的晚期非小细胞肺癌患者中的疗效:国际多中心EV-202期2研究

2025-07-090
OA
The impact of financial toxicity as a barrier to access and participation in early phase clinical trials for underrepresented populations using the COST-FACIT tool
2024-09-210
PRE
Understanding Barriers to Equity in Early Phase Clinical Trials Participation for the - Underrepresented Populations (uBEEP-UP Project)- A single-center survey-based study
2024-09-210
PRE
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study

Tgf β 抑制剂SAR439459作为单药治疗和与cemiplimab联合治疗晚期实体瘤患者的安全性,药代动力学,药效学和抗肿瘤活性: 1/1b期研究的结果

2024-06-191
OA
Final outcomes analysis of the cell product SQZ-PBMC-HPV Phase 1 trial in incurable HPV16+solid tumors shows improved overall survival in patients with increased CD8+T cell tumor infiltration
2024-05-021
PRE
Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort
2024-02-2010
OAAI
Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+patients with HPV16+solid tumors
2023-03-032
OAAI
PRELIMINARY CLINICAL EXPERIENCE WITH XMAB20717, A PD-1 X CTLA-4 BISPECIFIC ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS
2021-11-1014
OA
PHASE I/II TRIAL OF CABOZANTINIB PLUS DURVALUMAB IN ADVANCED GASTROESOPHAGEAL CANCER AND OTHER GASTROINTESTINAL MALIGNANCIES (CAMILLA): PHASE IB SAFETY AND EFFICACY RESULTS
2021-11-102
OA
A PHASE 1B MULTI-TUMOR COHORT STUDY OF CABOZANTINIB PLUS ATEZOLIZUMAB IN ADVANCED SOLID TUMORS: RESULTS OF THE TRIPLE-NEGATIVE BREAST CANCER, OVARIAN CANCER, AND ENDOMETRIAL CANCER COHORTS
2021-11-101
OA